Cover Image
市場調查報告書

Furiex Pharmaceuticals, Inc.:產品平台分析

Furiex Pharmaceuticals, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 294001
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Furiex Pharmaceuticals, Inc.:產品平台分析 Furiex Pharmaceuticals, Inc. - Product Pipeline Review - 2014
出版日期: 2014年06月10日 內容資訊: 英文 32 Pages
簡介

本報告提供Furiex Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Furiex Pharmaceuticals, Inc.的基本資料

Furiex Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Furiex Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Furiex Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Furiex Pharmaceuticals, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式

Furiex Pharmaceuticals, Inc.:藥物簡介

  • dapoxetine hydrochloride
  • eluxadoline
  • avarofloxacin hydrochloride

Furiex Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Furiex Pharmaceuticals, Inc.:最近的開發平台趨勢

Furiex Pharmaceuticals, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • RBx-10558

Furiex Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC05030CDB

Global Markets Direct's, 'Furiex Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Furiex Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Furiex Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Furiex Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Furiex Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Furiex Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Furiex Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Furiex Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Furiex Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Furiex Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Furiex Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Furiex Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Furiex Pharmaceuticals, Inc. Snapshot
    • Furiex Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Furiex Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Furiex Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Furiex Pharmaceuticals, Inc. - Pipeline Products Glance
    • Furiex Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Furiex Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
  • Furiex Pharmaceuticals, Inc. - Drug Profiles
    • dapoxetine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eluxadoline
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • avarofloxacin hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Furiex Pharmaceuticals, Inc. - Pipeline Analysis
    • Furiex Pharmaceuticals, Inc. - Pipeline Products by Target
    • Furiex Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Furiex Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Furiex Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Furiex Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Furiex Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • RBx-10558
  • Furiex Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Furiex Pharmaceuticals, Inc., Key Information
  • Furiex Pharmaceuticals, Inc., Key Facts
  • Furiex Pharmaceuticals, Inc. - Pipeline by Indication, 2014
  • Furiex Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Furiex Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Furiex Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014
  • Furiex Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014
  • Furiex Pharmaceuticals, Inc. - Phase III, 2014
  • Furiex Pharmaceuticals, Inc. - Phase II, 2014
  • Furiex Pharmaceuticals, Inc. - Pipeline by Target, 2014
  • Furiex Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014
  • Furiex Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014
  • Furiex Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Furiex Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014
  • Furiex Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014
  • Furiex Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Furiex Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014
  • Furiex Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Furiex Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Furiex Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014
  • Furiex Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Furiex Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Furiex Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top